XBiotech Inc. (XBIT): Price and Financial Metrics
Today's Latest Price: $17.11 USD
Oct 30 4:00pm Add XBIT to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
XBIT Stock Summary With a price/earnings ratio of 0.74, XBiotech Inc P/E ratio is greater than that of about merely 0.41% of stocks in our set with positive earnings. For XBIT, its debt to operating expenses ratio is greater than that reported by only 0.36% of US equities we're observing. Over the past twelve months, XBIT has reported earnings growth of -3,258.61%, putting it ahead of just 0.45% of US stocks in our set. Stocks with similar financial metrics, market capitalization, and price volatility to XBiotech Inc are WATT, IMAB, NVTA, PRTA, and GWRE. XBIT's SEC filings can be seen here. And to visit XBiotech Inc's official web site, go to www.xbiotech.com.
XBIT Price/Volume Stats
XBiotech Inc. (XBIT) Company Bio
XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.
XBIT Latest News Stream
All News Types
Commentary Corp. News Earnings Mgmt Change Product News Stock Offering
Loading, please wait...
Latest XBIT News From Around the Web
Below are the latest news stories about XBiotech Inc that investors may wish to consider to help them evaluate XBIT as an investment opportunity.
XBiotech (XBIT) announces that FDA issued an emergency use authorization for COVID-19 Convalescent Plasma as a COVID-19 treatment, thus opening door for the company’s antibody screening technology.The company collaborated with BioBridge Global to develop a test to accurately detect human antibodies present in patient blood that specifically attack the COVID-19 virus.BioBridge Global...
Stocks that moved heavily or traded substantially Monday: XBiotech, AstraZeneca rise; Churchill Downs, Gilead fall
The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood
After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021
Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy
Read More 'XBIT' Stories Here
XBIT Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7101 seconds.